PHARMACOLOGICAL APPROACH OF PLUMBAGIN, PIPERINE FOR IMPROVED BIOAVAILABILITY OF SOME ANTI-PSYCHOTIC DRUGS

Department of Pharmacology (M.pharm)

The current study standardizes the following models for schizophrenia-induced psychosis (Amphetamine/Dexamethasone/Apomorphine). To investigate the impact of Olanzapine alone and in combination with Plumbagin in Schizophrenia, using at least two dosages of each group and assess behavioral parameters (pharmacodynamics estimation). Using docking software, conduct pharmacokinetic experiments for bioavailability enhancement estimates and ADME studies for pharmacokinetics estimation. The objective of this study is the improvement in the bioavailability of this drug by using the agents which are the promising inhibitors of these sub enzymes of CYP namely plumbagin and piperine which ultimately may lead to an increase in bioavailability and increased in the duration of action of selected drug. In present study procurement of Drugs- Olanzapine, Dexamethasone, Plumbagin, Standardization of Models of Psychosis- Dexamethasone induced psychosis, Pharmacological Evaluation- Olanzapine alone and in combination with plumbagin by following models-Behavioural Models- Hyperactivity, Anhedonia (Splash Test), Stereotypy, Social Interaction Test are studied to enhance the bioavailability and activity of some anti- psychotic drugs. And also pharmacokinetic study for bioavailability estimation and In Silico studies for determination of ADME profiles of drugs are carried out.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.